^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    AFINITOR is a kinase inhibitor indicated for the treatment of:...Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Afinitor is indicated for the treatment of patients with advanced renal-cell carcinoma...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the NCCN Panel has included everolimus as a category 2A, other recommended option for patients with non-clear cell RCC.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Int J Cancer
    Title:

    Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial

    Published date:
    10/18/2020
    Excerpt:
    Patients with clear cell mRCC failing one initial VEGFR‐TKI received everolimus...Median PFS and median OS were 3.8 months (95%‐CI 3.2‐6.2) and 16.8 months (95%‐CI 14.3‐24.3). ORR was 7.9%, disease control rate 60.3%....Everolimus remains a safe and effective treatment option for mRCC patients...
    DOI:
    10.1002/ijc.33349